- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06147310
Effect Alb-PRF & A-PRF in Alveolar Ridge Preservation in Diabetes Patients - A RCCT (AlbPRFARP)
Effect of Albumin Gel-platelet-rich Fibrin (Alb-PRF) and Advanced Platelet-rich Fibrin (A-PRF) in Alveolar Ridge Preservation in Diabetes Patients - A Randomized Controlled Clinical Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Diabetes is a well-established risk factor for oral diseases that often lead to extractions and tooth loss in the population, while diabetic patients also have increased susceptibility to wound infections.
Albumin gel-platelet-rich fibrin (Alb-PRF) and advanced platelet-rich fibrin (A-PRF) are third-generation of platelet concentrates derived from a donor's blood by following a simple centrifugation protocol, heat treatment of platelet-poor plasma, and mixing of liquid-PRF from the same preparation.
This study proposes a novel alveolar ridge preservation technique based on the application of A-PRF inside the extraction socket to sustain the release of growth factors during the early wound healing phase, together with periosteum inhibition by overlaying an Alb-PRF membrane with slow biodegradation and space maintenance properties over the bone to reduce post-extraction alveolar ridge resorption.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Melissa R Fok
- Phone Number: 2859 0495
- Email: melfok@hku.hk
Study Contact Backup
- Name: Catherine Mok
- Phone Number: 2859 0301
- Email: cathmok@hku.hk
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
i. At least 18 years old with established TIIDM diagnosis for more than 0.5 years, fasting blood glucose ≥7.0 mmol/L or 2 h plasma glucose ≥11.1 mmol/L, maximum HbA1c levels under 8.0%.
ii. Non-smoker, diagnosed with generalized periodontitis stage III or IV. iii. Need for extraction of teeth, on opposing arches or opposing sides, with or without other concurrent indications for extractions: orthodontics, periodontitis, caries, fracture, root resorption, unrestorable root fragments.
iv. At least one adjacent teeth/ implant is present at the site of extraction with a secure prognosis.
v. No periapical lesions with a diameter of more than 5 mm (radiographically determined.
vi. Extraction socket with a bone height of at least 7mm at 2 walls. vii. Reasonably aligned dental arches viii. Will consider implant to replace missing teeth ix. Willing and able to give informed consent.
Exclusion Criteria:
i. Patients with conditions or circumstances, in the opinion of the Investigator, which would prevent completion of study participation or interfere with analysis of study results, such as history of non-compliance or unreliability.
ii. Pregnancy or intention to become pregnant at any point during the study duration.
iii. Smoker /alcoholic iv. Has platelet dysfunction/ thrombocytopenia/ blood dyscrasia v. On bisphosphonates or drugs that will significantly alter bone metabolism. vi. ASA III/IV.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Study Group
Alveolar ridge preservation with Alb-PRF + A-PRF after extraction
|
The tooth will be extracted automatically, tooth sectioning will be performed if necessary for multi-rooted teeth to minimize trauma.
Alveolar ridge preservation with blood platelet concentrate: heat-treated albumin (Alb-PRF) and advanced platelet-rich fibrin.
The experimental site will be filled with A-PRF plugs/membranes until level flushed with the level of bone.
An additional Alb-PRF membrane will be tucked and inserted below the buccal and oral flap.
Surgical flaps will not be raised.
Soft tissue will be tunnelled and undermined for insertion of the Alb-PRF membrane.
The extraction site and membranes will be stabilized by cross-mattress sutures and allowed for secondary intention healing.
Other Names:
|
|
Placebo Comparator: Control Group
Spontaneous healing after extraction
|
The tooth will be extracted automatically, tooth sectioning will be performed if necessary for multi-rooted teeth to minimize trauma.
Cross mattress suture will be applied and site allowed to heal naturally.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Ridge horizontal width
Time Frame: Up to 20 weeks
|
Ridge horizontal width changes (1mm, 3mm, 5mm apical to most coronal crest at buccal/oral) Method: CBCT
|
Up to 20 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Ridge height
Time Frame: Up to 20 weeks
|
Ridge height changes (buccal and oral) Method: CBCT
|
Up to 20 weeks
|
|
Ridge volume and profile
Time Frame: Up to 20 weeks
|
Changes in ridge volume and profilometric changes Method: Intraoral scan, CBCT
|
Up to 20 weeks
|
|
Keratinized tissue width changes
Time Frame: Up to 20 weeks
|
Changes in keratinized tissue width Method: Periodontal probe with fixed landmarks
|
Up to 20 weeks
|
|
Cytokines and growth factors
Time Frame: Up to 56 days
|
Changes in concentrations of cytokines and growth factors in wound fluid during early to mid-term wound healing events
|
Up to 56 days
|
|
Implant planning related outcome
Time Frame: Up to 20 weeks
|
Ability to place prosthetically guided implant, need for additional augmentation
|
Up to 20 weeks
|
|
Histological assessment
Time Frame: Up to 24 weeks
|
Bone volume to total tissue volume ratio and bone microstructure Method: Core biopsy with trephine at day of implant placement, micro CT and histomorphometric assessment
|
Up to 24 weeks
|
|
Patient-reported outcome measures
Time Frame: Up to 28 days
|
Patient will be asked to record their pre-operative anxiety level, intraoperative pain level and pain levels at follow up visits on a visual analogue scale (0-10)
|
Up to 28 days
|
|
Inflammatory proliferative remodelling
Time Frame: Up to 28 days
|
IPR score will be assessed by independent assessors with photos of wound site at different itme points
|
Up to 28 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Melissa Fok, The University of Hong Kong
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- L2023_01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tooth Extraction Status Nos
-
Assistance Publique - Hôpitaux de ParisURC-CIC Paris Descartes Necker Cochin; DENTOSCompleted
-
Tufts UniversityCompletedTooth Extraction Status Nos
-
Plovdiv Medical UniversityCompletedTooth Extraction Status NosBulgaria
-
Gustavo Avila-Ortiz DDS, MS, PhDCompleted
-
reyhansaglamCompleted
-
The European Research Group on Periodontology (ERGOPerio)The University of Hong KongCompletedTooth Extraction Status Nos
-
Necmettin Erbakan UniversityCompleted
-
TC Erciyes UniversityCompletedTooth Extraction Status NosTurkey
-
Adrià Jorba GarcíaNot yet recruitingTooth Extraction Status Nos | Bone SubstitutesSpain
-
University of BarcelonaCompletedAnesthesia, Local | Tooth Extraction Status NosSpain
Clinical Trials on Study Group
-
New Ismailia National UniversityCompleted
-
Romanian Society of Anesthesia and Intensive CareUniversity of Medicine and Pharmacy "Victor Babes" Timisoara; Timişoara County...Completed
-
Istanbul Sureyyapasa Chest Diseases and Chest Surgery...CompletedSleep Disorder | Obstructive Sleep Apnea of Adult | Patient ComplianceTurkey
-
Cairo UniversityCompletedCarpal Tunnel Syndrome
-
Muş Alparlan UniversityNot yet recruitingSTROKE REHABİLİTATİONTurkey
-
Medical University of GrazRoyal Alexandra HospitalCompletedBrain Injuries | Preterm Infant | Birth HypoxiaAustria, Canada, Ireland, Slovenia, Germany, Poland, Italy
-
Mehmet GÖĞREMİŞKahramanmaras Sutcu Imam UniversityCompletedFemale Patients Diagnosed With LDH at L4-S1Turkey
-
Alanya Alaaddin Keykubat UniversityCompletedTemporomandibular Joint Disorders | Physiotherapy | Vertigo, Paroxysmal | Soft Tissue Mobilisation | Vestibular ExercisesTurkey
-
Loma Linda UniversityTerminatedType 1 Diabetes Mellitus
-
Medtronic BRCMedtronicCompletedAtrial Fibrillation | Sinus ArrhythmiaItaly